-
Mashup Score: 3Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach | Blood Cancer Talks | Episode 54 - 2 month(s) ago
In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM….
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 42Episode 42. CAR T-cell Therapy in Early Relapsed Myeloma with Dr. Samer Al Hadidi | Blood Cancer Talks | Episode 43 - 2 month(s) ago
In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel):…
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
Tune in to our new episode on CAR T-cell therapy in early relapsed #MultipleMyeloma with @HadidiSamer! We dissect the data presented at @FDAOncology ODAC and how to make sense of it in clinical practice as we anticipate approval soon! https://t.co/4kWqQPcFFo https://t.co/8aKWnLeG0m
-
-
Mashup Score: 1Episode 51. Venetoclax in AML with Dr. Andrew Wei | Blood Cancer Talks | Episode 52 - 2 month(s) ago
In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode: 1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa20129712. 10 day Decitabine plus venetoclax for ND AML…
Source: share.transistor.fmCategories: General Medicine News, Partners & KOLsTweet-
1. Venetoclax in AML with Andrew Wei @PeterMacCC ! We discussed the history of venetoclax development and practical tidbits on managing AML with venetoclax-based regimens! https://t.co/WFqqrYi2EP
-
-
Mashup Score: 1
Dr. John Fleetham chats with Dr. Ludovico Messineo and Dr. Simon Joosten about their articles “Hypnotics on Obstructive Sleep Apnea Severity and Endotypes: A Systematic Review and Meta-Analysis” and “The Arousal Threshold: The ‘Weakest Link’ in OSA Pathogenesis.”
Source: share.transistor.fmCategories: General Medicine News, PulmonologyTweet-
Don't miss the latest episode of #OutoftheBlue! This week's episode: Hypnotics on Obstructive Sleep Apnea Severity and Endotypes: A Systematic Review and Meta-Analysis” and “The Arousal Threshold: The ‘Weakest Link’ in O... Listen Here 🔈 https://t.co/xpTsLX4kaF
-
-
Mashup Score: 0
Dr. Michael Lanspa chats with Dr. Hannah Wunsch about her paper, “Evaluation of Etomidate Use and Association with Mortality Compared with Ketamine among Critically Ill Patients.”
Source: share.transistor.fmCategories: General Medicine News, PulmonologyTweet-
Don't miss the latest episode of #OutoftheBlue! This week's episode: Evaluation of Etomidate Use and Association with Mortality Compared with Ketamine among Critically Ill Patients Listen Here 🔈 https://t.co/uvlldbE0kv
-
-
Mashup Score: 8
In this week’s podcast, we’ll learn about targeting mutant calreticulin in MPNs, or myeloproliferative neoplasms. Then, it’s time to address bleeding and clotting in cancer. Results of the prospective, observational CAT-BLED study provide much needed data on the high risk of clinically relevant…
Source: share.transistor.fmCategories: General Medicine News, Oncologists1Tweet-
📣Listen to this episode of the Blood Podcast featuring "Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH". #BloodPodcast #BloodJournals https://t.co/z7nyx1LWZb https://t.co/mwTZVn03Ny
-
-
Mashup Score: 5Enhancing Risk Stratification for Pediatric B-Cell Acute Lymphoblastic Leukemia: No Longer a ‘PI’ in the Sky Idea? | The Hematologist | Episode 147 - 4 month(s) ago
In this episode, Contributing Editor Lauren Pommert, MD, a pediatric oncologist specializing in children with leukemia at Cincinnati Children’s in Cincinnati, Ohio, talks with Natalie DelRocco, PhD, a senior statistician for the Children’s Oncology Group’s Bone Tumors Committee and an assistant…
Source: share.transistor.fmCategories: General Medicine News, Oncologists1Tweet-
🔊 New podcast episode! A conversation with Natalie DelRocco, PhD, co-author of the recent paper “Enhanced Risk Stratification for Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report." Listen here: https://t.co/p6gi6WBLja https://t.co/2ivDsyI1V0
-
-
Mashup Score: 3Dr. Brennan Spiegel (Cedars-Sinai): AI in healthcare: Will AI help humans to thrive? | In AI We Trust? | Episode 96 - 4 month(s) ago
In this episode of #InAIWeTrust, Dr. Brennan Spiegel, Cedars-Sinai Director of Health Services Research and Chair of Digital Health Ethics, discusses his use of AI for increased efficiencies and to improve patient care, including co-founding Xaia, an AI mental health tool. He talks about the…
Source: share.transistor.fmCategories: General Medicine News, Future of MedicineTweet-
"Doctors will not be replaced by #AI but doctors using AI will replace those who don't," paraphrasing @BrennanSpiegel in his podcast of In AI We Trust @in_ai_we_trust https://t.co/69gaUM4o4e
-
-
Mashup Score: 0
Dr. Michael Lanspa chats with Dr. Anthony Gordon about his article, “From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU.”
Source: share.transistor.fmCategories: General Medicine News, PulmonologyTweet-
Don't miss the latest episode of #OutoftheBlue! This week's episode: From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU Listen Here 🔈 https://t.co/PXAis7jj8P
-
-
Mashup Score: 15Board Review Bonus 2: Minimal Change Disease | GN in Ten | Episode - 5 month(s) ago
In this special bonus episode of the podcast, Koyal and Kenar provide a maximally useful review of minimal change disease, from diagnosis (including secondary causes to screen for) to treatment options, including how to decide which patients may do better with which therapies. Can’t get enough…
Source: share.transistor.fmCategories: General Medicine News, NephrologyTweet-
I found a great episode of ''GN in Ten''. On board review material on minimal change disease https://t.co/qDg5N6nk60 @ISGDtweets @koyaljainMD
-
3. The comeback of belantamab with @HangQuach1 @StVHealthAust! We had a wide-ranging discussion on DREAMM-7 and 8 RCTs, ocular toxicity of belantamab, and how will it fit into the current treatment paradigm! https://t.co/05A4bO4Gle